Circulating cytokines in predicting development of severe acute pancreatitis

Anne Nieminen, Mikael Maksimow, Panu Mentula, Lea Kyhälä, Leena Kylänpää, Pauli Puolakkainen, Esko Kemppainen, Heikki Repo, Marko Salmi, Anne Nieminen, Mikael Maksimow, Panu Mentula, Lea Kyhälä, Leena Kylänpää, Pauli Puolakkainen, Esko Kemppainen, Heikki Repo, Marko Salmi

Abstract

Introduction: Severe acute pancreatitis (AP) is associated with high morbidity and mortality. Early prediction of severe AP is needed to improve patient outcomes. The aim of the present study was to find novel cytokines or combinations of cytokines that can be used for the early identification of patients with AP at risk for severe disease.

Methods: We performed a prospective study of 163 nonconsecutive patients with AP, of whom 25 had severe AP according to the revised Atlanta criteria. Admission serum levels of 48 cytokines and growth factors were determined using Bio-Plex Pro Human Cytokine Assay 21-plex and 27-plex magnetic bead suspension panels. Admission plasma levels of C-reactive protein (CRP), creatinine and calcium were measured for comparison. In subgroup analyses, we assessed the cytokine profiles of patients with severe AP (n = 14) who did not have organ dysfunction (OD) upon admission (modified Marshall score <2).

Results: Of 14 cytokines elevated in the severe AP group, interleukin 6 (IL-6) and hepatocyte growth factor (HGF) levels were independent prognostic markers of severe AP. IL-6, HGF and a combination of them predicted severe AP with sensitivities of 56.0%, 60.0% and 72.0%, respectively, and specificities of 90.6%, 92.8% and 89.9%, respectively. The corresponding positive likelihood ratio (LR+) values were 5.9, 8.3 and 7.1, respectively. The predictive values of CRP, creatinine and calcium were comparable to those of the cytokines. In subgroup analyses of patients with severe AP and without OD upon admission, we found that IL-8, HGF and granulocyte colony-stimulating factor (G-CSF) levels predicted the development of severe AP, with G-CSF being the most accurate cytokine at a sensitivity of 35.7%, a specificity of 96.1% and a LR+ of 9.1.

Conclusions: IL-6 and HGF levels upon admission have prognostic value for severe AP which is similar to levels of CRP, creatinine and calcium. Although IL-6 and HGF, as either single or combined markers, were not perfect in identifying patients at risk for severe AP, the possibility that combining them with novel prognostic markers other than cytokines might improve prognostic accuracy needs to be studied. The accuracy of IL-8, HGF and G-CSF levels in predicting severe AP in patients without clinical signs of OD upon admission warrants larger studies.

Figures

Figure 1
Figure 1
Patient classifications according to modified Marshall score [[20]] and revised Atlanta criteria [[1]] upon admission. MMS, Modified Marshall score.
Figure 2
Figure 2
Receiver operating characteristic curves of C-reactive protein and interleukin 6 plus hepatocyte growth factor for prediction of severe acute pancreatitis in the entire acute pancreatitis patient cohort (N = 163). Boxes indicate clinically optimal cutoff points used to calculate the sensitivity and specificity of each biomarker listed in Table 5. CRP, C-reactive protein; HGF, Hepatocyte growth factor; IL, Interleukin.
Figure 3
Figure 3
Receiver operating characteristic curves of granulocyte colony-stimulating factor and C-reactive protein for prediction of severe acute pancreatitis in patients with admission modified Marshall scores <2 (N = 142). Boxes indicate clinically optimal cutoff points used to calculate the sensitivity and specificity of each biomarker given in Table 7. CRP, C-reactive protein; G-CSF, Granulocyte colony-stimulating factor; MMS, Modified Marshall score.

References

    1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111. doi: 10.1136/gutjnl-2012-302779.
    1. Halonen KI, Leppaniemi AK, Puolakkainen PA, Lundin JE, Kemppainen EA, Hietaranta AJ, Haapiainen RK. Severe acute pancreatitis: prognostic factors in 270 consecutive patients. Pancreas. 2000;21:266–271. doi: 10.1097/00006676-200010000-00008.
    1. Gloor B, Müller CA, Worni M, Martignoni ME, Uhl W, Büchler MW. Late mortality in patients with severe acute pancreatitis. Br J Surg. 2001;88:975–979. doi: 10.1046/j.0007-1323.2001.01813.x.
    1. McKay CJ, Buter A. Natural history of organ failure in acute pancreatitis. Pancreatology. 2003;3:111–114. doi: 10.1159/000070078.
    1. Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT, Baron TH, Farnell MB, Sarr MG. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis.”. Am J Gastroenterol. 2009;104:710–715. doi: 10.1038/ajg.2008.77.
    1. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. 1998;175:76–83. doi: 10.1016/S0002-9610(97)00240-7.
    1. Kylänpää ML, Repo H, Puolakkainen PA. Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol. 2010;16:2867–2872. doi: 10.3748/wjg.v16.i23.2867.
    1. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg. 2002;89:298–302. doi: 10.1046/j.0007-1323.2001.02025.x.
    1. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53:1340–1344. doi: 10.1136/gut.2004.039883.
    1. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–2400. doi: 10.1111/j.1572-0241.2006.00856.x.
    1. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022–2044. doi: 10.1053/j.gastro.2007.03.065.
    1. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Rückauer K, Andreesen R, Farthmann EH, Schölmerich J. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology. 1991;101:782–785.
    1. Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Crit Care Med. 1999;27:749–755. doi: 10.1097/00003246-199904000-00029.
    1. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol. 1999;94:213–218. doi: 10.1111/j.1572-0241.1999.00709.x.
    1. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut. 2000;47:546–552. doi: 10.1136/gut.47.4.546.
    1. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–1652. doi: 10.1097/00003246-199510000-00007.
    1. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–872. doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>;2-E.
    1. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–1135. doi: 10.1016/S0895-4356(03)00177-X.
    1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443. doi: 10.1038/342440a0.
    1. Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. Pancreatology. 2009;9:777–785. doi: 10.1159/000214191.
    1. Ueda T, Takeyama Y, Toyokawa A, Kishida S, Yamamoto M, Saitoh Y. Significant elevation of serum human hepatocyte growth factor levels in patients with acute pancreatitis. Pancreas. 1996;12:76–83. doi: 10.1097/00006676-199601000-00010.
    1. Espinosa L, Linares PM, Bejerano A, Lopez C, Sanchez A, Moreno-Otero R, Gisbert JP. Soluble angiogenic factors in patients with acute pancreatitis. J Clin Gastroenterol. 2011;45:630–637. doi: 10.1097/MCG.0b013e31820d3533.
    1. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62–69. doi: 10.1136/gut.48.1.62.
    1. Harrison DA, D’Amico G, Singer M. Case mix, outcome, and activity for admissions to UK critical care units with severe acute pancreatitis: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care. 2007;11:S1.
    1. Wu BU, Conwell DL. Update in acute pancreatitis. Curr Gastroenterol Rep. 2010;12:83–90. doi: 10.1007/s11894-010-0091-6.
    1. Oiva J, Mustonen H, Kylänpää ML, Kyhälä L, Kuuliala K, Siitonen S, Kemppainen E, Puolakkainen P, Repo H. Acute pancreatitis with organ dysfunction associates with abnormal blood lymphocyte signaling: controlled laboratory study. Crit Care. 2010;14:R207. doi: 10.1186/cc9329.
    1. Chakraborty S, Kaur S, Muddana V, Sharma N, Wittel UA, Papachristou GI, Whitcomb D, Brand RE, Batra SK. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol. 2010;105:2050–2059. doi: 10.1038/ajg.2010.23.
    1. Yilmaz G, Köksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem. 2011;44:1227–1230. doi: 10.1016/j.clinbiochem.2011.07.006.
    1. Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C. A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients. Clin Drug Investig. 2012;32:179–187. doi: 10.2165/11598610-000000000-00000.
    1. Oiva J, Mustonen H, Kylänpää ML, Kuuliala K, Siitonen S, Kemppainen E, Puolakkainen P, Repo H. Patients with acute pancreatitis complicated by organ dysfunction show abnormal peripheral blood polymorphonuclear leukocyte signaling. Pancreatology. 2013;13:118–124. doi: 10.1016/j.pan.2013.01.010.
    1. Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis—a systems biology approach. Crit Care. 2013;17:231. doi: 10.1186/cc12693.
    1. Kylänpää-Bäck ML, Takala A, Kemppainen E, Puolakkainen P, Kautiainen H, Jansson SE, Haapiainen R, Repo H. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scand J Gastroenterol. 2001;36:1100–1107. doi: 10.1080/003655201750422738.
    1. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. 2006;12:151–170. doi: 10.1179/096805106X102246.
    1. Caldwell CC, Hotchkiss RS. The first step in utilizing immune-modulating therapies: immune status determination. Crit Care. 2011;15:108. doi: 10.1186/cc9397.

Source: PubMed

3
Tilaa